Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults

Bernold Kenteu, Jean Jacques N Noubiap, Martine Claude Etoa, Marcel Azabji-Kenfack, Mesmin Dehayem, Eugene Sobngwi, Bernold Kenteu, Jean Jacques N Noubiap, Martine Claude Etoa, Marcel Azabji-Kenfack, Mesmin Dehayem, Eugene Sobngwi

Abstract

Background: Cases of severe hypoglycaemia were reported in HIV/AIDS patients receiving high dose of the sulfonylurea co-trimoxazole for opportunistic infections. Whether co-trimoxazole at prophylactic dose would induce similar side effects is unknown. We aimed to investigate the acute effects of co-trimoxazole at prophylactic dose on glucose metabolism in healthy adults.

Methods: We enrolled 20 healthy volunteers (15 males and 5 females) aged 23.0 (SD 2.0) years, with mean BMI of 22.3 (SD 3.6) Kg/m2 with normal glucose tolerance, hepatic and renal function. We performed a 75-g oral glucose tolerance test (OGTT) with and without concomitant oral co-trimoxazole administered 60 min before the test. Blood glucose response was measured using a capillary test at baseline and at 30, 60, 90, 120 and 180 min following oral glucose load on the two occasions. C-peptide response was also measured. Absolute values of blood glucose and C-peptide with and without co-trimoxazole were compared using the Wilcoxon test.

Results: During the OGTT without co-trimoxazole (control) vs. the OGTT with co-trimoxazole (test), the glycaemia varied from 4.83 (SD 0.39) mmol/l vs. 4.72 (SD 0.28) mmol/l at T0 (P = 0.667), to 8.00 (SD 1.11) mmol/l vs. 7.44 (SD 0.78) mmol/l at T30 (P = 0.048), 8.00 (SD 1.17) mmol/l vs. 7.67 (SD 1.00) mmol/l at T60 (P = 0.121), 7.33 (SD 0.94) mmol/l vs. 7.11 (SD 0.83) mmol/l at T90 (P = 0.205), 6.78 (SD 1.00) mmol/l vs. 6.67 (SD 1.00) mmol/l at T120 (P = 0.351) and 4.72 (SD 1.39) mmol/l vs. 4.72 (SD 1.56) mmol/l at T180 (P = 0.747). The ratio of area under the glycaemia curve during the control and test investigation was 96.7 %, thus a 3.3 decreased glycaemic response (p = 0.062). A decrease of glycaemia by more than 10 % occurred in 6/20 participants at T30, 7/20 participants at T60 and 1/20 participant at T30 and T60. None of the volunteers experienced co-trimoxazole-induced hypoglycaemia. At the same time, the C-peptide response during the control vs. the test investigation varied from 278.1 (SD 57.5) pmol/l vs. 242.8 (SD 42.5) pmol/l at T0 (P = 0.138), to 1845.6 (SD 423.6) pmol/l vs. 2340.6 (SD 701.3) pmol/l at T60 (P = 0.345) and 1049.8 (SD 503.1) pmol/l vs. 1041.63 (SD 824.21) pmol/l at T180 (P = 0.893).

Conclusion: Ninety minutes after its administration, co-trimoxazole induced a significant reduction of the early glycaemic response to oral glucose in parallel with a 27-% increase in insulin secretory response. Co-trimoxazole induced within 120 min a more than 10-% blood glucose reduction in 2/3 of participants. However none of the volunteers experienced hypoglycaemia.

Keywords: Adults; Co-trimoxazole; Glycaemia.

Figures

Fig. 1
Fig. 1
Test versus control OGTT: Compared glycaemic response. Caption: x-axis: time in minutes, y-axis glycemia in mmol/l
Fig. 2
Fig. 2
Test versus control OGTT: compared C-peptide secretory response. Caption: x-axis: time in minutes, y-axis c-peptide in pmol/l

References

    1. Cheng W, Wu Y, Wen Y, Ma Y, Zhao D, Dou Z, et al. Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China. Bull World Health Organ. 2015;93(3):152–60. doi: 10.2471/BLT.14.142745.
    1. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet Lond Engl. 2004;364(9443):1428–34. doi: 10.1016/S0140-6736(04)17225-5.
    1. Ho JM-W, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ. 2011;183(16):1851–8. doi: 10.1503/cmaj.111152.
    1. Strevel EL, Kuper A, Gold WL. Severe and protracted hypoglycaemia associated with co-trimoxazole use. Lancet Infect Dis. 2006;6(3):178–82. doi: 10.1016/S1473-3099(06)70414-5.
    1. Nunnari G, Celesia BM, Bellissimo F, Tosto S, La Rocca M, Giarratana F, et al. Trimethoprim-sulfamethoxazole-associated severe hypoglycaemia: a sulfonylurea-like effect. Eur Rev Med Pharmacol Sci. 2010;14(12):1015–8.
    1. Schelleman H, Bilker WB, Brensinger CM, Wan F, Hennessy S. Anti-infectives and risk of severe hypoglycemia in glipizide and glyburide users. Clin Pharmacol Ther. 2010;88(2):214–22. doi: 10.1038/clpt.2010.74.
    1. Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest. 1987;79(3):777–81. doi: 10.1172/JCI112884.
    1. Hekimsoy Z, Biberoǧlu S, Çömlekçi A, Tarhan O, Mermut C, Biberoǧlu K. Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection. Eur J Endocrinol. 1997;136(3):304–6. doi: 10.1530/eje.0.1360304.
    1. Arem R, Garber AJ, Field JB. Sulfonamide-induced hypoglycemia in chronic renal failure. Arch Intern Med. 1983;143(4):827–9. doi: 10.1001/archinte.1983.00350040217036.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe